Clinical implication of FMR1 intermediate alleles in a Spanish population
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Alvarez-Mora, MI
- Madrigal, I
- Tejada, MI
- Izquierdo-Alvarez, S
- de Saz, PSV
- Villate, O
- Rodriguez-Santiago, B
- Jurado, LAP
- Rodriguez-Revenga, L
- Mila, M
Grupos
Abstract
FMR1 premutation carriers (55-200 CGGs) are at risk of developing Fragile X-associated primary ovarian insufficiency as well as Fragile X-associated tremor/ataxia syndrome. FMR1 premutation alleles are also associated with a variety of disorders, including psychiatric, developmental, and neurological problems. However, there is a major concern regarding clinical implications of smaller CGG expansions known as intermediate alleles (IA) or gray zone alleles (45-54 CGG). Although several studies have hypothesized that IA may be involved in the etiology of FMR1 premutation associated phenotypes, this association still remains unclear. The aim of this study was to provide new data on the clinical implications of IA. We reviewed a total of 17 011 individuals: 1142 with primary ovarian insufficiency, 478 with movement disorders, 14 006 with neurodevelopmental disorders and 1385 controls. Similar IA frequencies were detected in all the cases and controls (cases 1.20% vs controls 1.39%, P = .427). When comparing the allelic frequencies of IA 50CGGs, a greater, albeit not statistically significant, number of alleles were detected in all the cohorts of patients. Therefore, IA below 50 CGGs should not be considered as risk factors for FMR1 premutation-associated phenotypes, at least in our population. However, the clinical implication of IA 50CGGs remains to be further elucidated.
Datos de la publicación
- ISSN/ISSNe:
- 0009-9163, 1399-0004
- Tipo:
- Article
- Páginas:
- 153-158
- DOI:
- 10.1111/cge.13257
- Factor de Impacto:
- 1,679 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
CLINICAL GENETICS WILEY
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Keywords
- FMR1 intermediate alleles; genetic counseling; gray zone; movement disorders; neurodevelopmental disorders; primary ovarian insufficiency
Proyectos asociados
RED DE BIOBANCOS (BIOBANCOS)
RD09/0076/00021 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010
COMPREHENSIVE, INTEGRATIVE AND GENOMIC APPROACH TO THE UNDERSTANDING AND TREATMENT OF CANCER AND LEUKEMIA.
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
PIE13/00046 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014
LA RUTA DE LA OXITOCINA EN LOS TRASTORNOS DEL ESPECTRO AUTISTA: IMPORTANCIA DE LAS VARIANTES GENÉTICAS CON RELEVANCIA FUNCIONAL.
Investigador Principal: CARMEN ORELLANA ALONSO
2014_0056_CRC_ORELLANA . 2014
ABORDAJE GENÓMICO PARA LA IDENTIFICACIÓN DE NUEVOS GENES Y MÓDULOS FUNCIONALES RESPONSABLES DE DISCAPACIDAD INTELECTUAL GRAVE.
Investigador Principal: FRANCISCO MARTÍNEZ CASTELLANO
PI14/00350 . INSTITUTO DE SALUD CARLOS III . 2015
NUEVA APROXIMACIÓN GENÓMICA PARA EL DIAGNÓSTICO DE AUTISMO Y DISCAPACIDAD INTELECTUAL: IMPORTANCIA DE LAS MUTACIONES ADQUIRIDAS EN MOSAICISMO SOMÁTICO Y DE NUEVOS GENES CANDIDATOS.
Investigador Principal: SANDRA MONFORT MEMBRADO
2018_0170_CRC_MUTUA MADRILEÑA_MONFORT . FUNDACION MUTUA MADRILEÑA . 2018
Cita
Alvarez MI,Madrigal I,Martinez F,Tejada MI,Izquierdo S,de Saz PSV,Caro A,Villate O,Rodriguez B,Jurado L,Rodriguez L,Mila M. Clinical implication of FMR1 intermediate alleles in a Spanish population. Clin Genet. 2018. 94. (1):p. 153-158. IF:4,104. (1).